Bladder urachal carcinoma

Summary

Bladder urachal carcinoma (MONDO:0003715) is a cancer. A subtype of urinary bladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder urachal carcinoma
Mondo ID	MONDO:0003715
MeSH	C536475
Orphanet	695020
DOID	DOID:5958
NCIT	C39842
UMLS	C2931202
MedGen	419015
Is cancer (heuristic)	yes

Also known as: bladder urachal cancer · bladder urachal carcinoma · urachal carcinoma

Data availability: 1 cell line.

Disease family

This is a subtype of urinary bladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › bladder urachal carcinoma

Related subtypes (8): bladder adenocarcinoma, bladder squamous cell carcinoma, urinary bladder small cell neuroendocrine carcinoma, stage IVb bladder cancer, superficial urinary bladder carcinoma, bladder transitional cell carcinoma, childhood bladder carcinoma, bladder small cell carcinoma

Subtypes (3): bladder urachal squamous cell carcinoma, bladder urachal urothelial carcinoma, bladder urachal adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.